Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) is a complete three-drug HIV treatment regimen that combines a novel integrase inhibitor with proven nucleoside analogs for once-daily oral therapy. This single-tablet regimen treats HIV-1 infection in adults and pediatric patients weighing at least 14 kg, offering both treatment-naive and treatment-experienced options with high efficacy and improved safety profiles. For patients seeking affordable HIV treatment options, working with qualified healthcare providers ensures proper viral load monitoring, resistance testing, and comprehensive HIV care management with appropriate medical oversight for this complex chronic condition.
